PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10747524

Plateletapheresis: instrumentation validation.

E A Burgstaler·A A Pineda
View original source ↗Export metadata ↓

Abstract

Plateletapheresis instrumentation validation is required to document that a new or modified instrument or technique is capable of consistently producing acceptable products at the production center using their equipment, personnel, and counting techniques even though the instrument or technique may already have FDA or equivalent approval for use. To pursue the process of validation, several questions need to be addressed: when is it required, what products are validated, what parameters are monitored, and how many products are required. Validation is required when a new instrument or technique (process) is used that could affect the quality of the product. According to the FDA, each apheresis system (e.g., Spectra LRS, Amicus) and each type of product (e.g., single, double, triple) need to be validated separately. Parameters to be validated vary, but usually platelet (plt) yield, white blood cell (WBC) content (if products are labeled "leukoreduced"), and 5-day storage pH are monitored. The number of procedures monitored is also quite variable, but we use 20 samples for highly variable parameters such as platelet yield and WBC content and five samples for less variable parameters such as 5-day storage pH. As an example, we validated the Fenwal Amicus (Baxter Biotech) for single apheresis platelet products. With 20 samples, we found that: 85% of the products contained > or = 3 x 10(11) plt (requirement was at least 75% contain > or = 3 x 10(11) plt); platelet concentration of all products was < or = 1.515 x 10(6) plt/microL (requirement was < or = 2.435 x 10(6) plt/microL), and WBC content was < 1 x 10(6) WBC in all products (requirement was all products contain < 5 x 10(6) WBC). In addition, in five samples, the 5-day storage pH was 6.89-7.25 (requirement was all products should be > or = 6.2 pH). Once validation is complete and acceptable, the process should be monitored on a regular basis using some form of process control. Statistical process control programs are available that can assist in documenting validation and ongoing process control. With the use of process validation and ongoing process control, the plateletapheresis center can assure that acceptable products are consistently being produced.

Explore related subjects

Forms and Records ControlHumansHydrogen-Ion ConcentrationPlateletpheresisProcess Assessment, Health CareQuality Assurance, Health CareJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E A Burgstaler, A A Pineda. 1999. Plateletapheresis: instrumentation validation.. https://doi.org/10.1016/s0955-3886(99)00087-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Medicare program; hospital outpatient prospective payment system and CY 2007 payment rates; CY 2007 update to the ambulatory surgical center covered procedures list; Medicare administrative contractors; and reporting hospital quality data for FY 2008 inpatient prospective payment system annual payment update program--HCAHPS survey, SCIP, and mortality. Final rule with comment period and final rule.

This final rule with comment period revises the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system, and to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 and the Deficit Reduction Act (DRA) of 2005. In this final rule with comment period, we describe changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2007. In addition, this final rule with comment period implements future CY 2009 required reporting on quality measures for hospital outpatient services paid under the prospective payment system. This final rule with comment period revises the current list of procedures that are covered when furnished in a Medicare-approved ambulatory surgical center (ASC), which are applicable to services furnished on or after January 1, 2007. This final rule with comment period revises the emergency medical screening requirements for critical access hospitals (CAHs). This final rule with comment period supports implementation of a restructuring of the contracting entities responsibilities and functions that support the adjudication of Medicare fee-for-service (FFS) claims. This restructuring is directed by section 1874A of the Act, as added by section 911 of the MMA. The prior separate Medicare intermediary and Medicare carrier contracting authorities under Title XVIII of the Act have been replaced with the Medicare Administrative Contractor (MAC) authority. This final rule continues to implement the requirements of the DRA that require that we expand the "starter set" of 10 quality measures that we used in FY 2005 and FY 2006 for the hospital inpatient prospective payment system (IPPS) Reporting Hospital Quality Data for the Annual Payment Update (RHQDAPU) program. We began to adopt expanded measures effective for payments beginning in FY 2007. In this rule, we are finalizing additional quality measures for the expanded set of measures for FY 2008 payment purposes. These measures include the HCAHPS survey, as well as Surgical Care Improvement Project (SCIP, formerly Surgical Infection Prevention (SIP)), and Mortality quality measures.

Forms and Records Control↗